TRANSCEND 004: Highlights from ASH 2024

Opinion
Video

Experts examine the potential role of chimeric antigen receptor (CAR) T-cell therapy in chronic lymphocytic leukemia treatment, incorporating new evidence presented at the 66th American Society of Hematology Annual Meeting and Exposition 2024.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Newsletter

      Stay up to date on practice-changing data in community practice.

      Subscribe Now!
      Recent Videos
      3 experts are featured in this series.
      COMFORT Trials: Applying Evidence to Intermediate-Risk Myelofibrosis
      3 experts are featured in this series.
      Myelofibrosis Management: Clinical Approaches and Treatment Algorithms With Case-Based Application
      Clinical Impact of COCOON: Advancing Dermatologic AE Management
      Clinical Impact of COCOON: Advancing Dermatologic AE Management
      Clinical Decision-Making Framework for Initiating Myelofibrosis Therapy
      Clinical Decision-Making Framework for Initiating Myelofibrosis Therapy
      Clinical Approaches for Dermatologic AEs Associated With Amivantamab + Lazertinib in Advanced NSCLC
      Clinical Approaches for Dermatologic AEs Associated With Amivantamab + Lazertinib in Advanced NSCLC
      Prognostic Stratification on Myelofibrosis: From Models to Clinical Application
      Prognostic Stratification on Myelofibrosis: From Models to Clinical Application
      First-Line CLL/SLL: Is Chemo-Free the Future?
      First-Line CLL/SLL: Is Chemo-Free the Future?
      1 expert is featured in this series.
      Ruxolitinib Therapy for cGVHD: Insights on Patient and Safety Monitoring
      3 experts are featured in this series.
      Personalized JAK Inhibitor Selection in Myelofibrosis: Clinical Characteristics, Molecular Profiles, and Treatment Sequencing
      3 experts are featured in this series.
      Advancing Treatment Paradigms in Myeloproliferative Neoplasms: From Molecular Pathogenesis to Patient-Tailored Therapy
      Related Content
      Analysis Illuminates CAR T-Cell Optimization for CLL

      Analysis Illuminates CAR T-Cell Optimization for CLL

      Morgan Bayer
      April 17th 2025
      Article

      Fewer prior therapies with liso-cel in chronic lymphocytic leukemia showed improved overall response rate in TRANSCEND-CLL-004 analysis.

      Read More

      Understanding the Role of Zanubrutinib for the Treatment of CLL

      Understanding the Role of Zanubrutinib for the Treatment of CLL

      Rohit Gosain, MD;Rahul Gosain, MD
      April 23rd 2024
      Podcast

      Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.

      Listen

      Incorporating MRD into Monitoring After Fixed-Duration CLL Treatment

      Incorporating MRD into Monitoring After Fixed-Duration CLL Treatment

      Targeted Oncology Staff
      April 7th 2025
      Article

      During a Case-Based Roundtable® event, John N. Allan, MD, discussed the addition of anti-CD20 antibody and the use of MRD following fixed-duration treatment of chronic lymphocytic leukemia.

      Read More

      Exciting Activity in Chronic Lymphocytic Leukemia

      Exciting Activity in Chronic Lymphocytic Leukemia

      Nichole Tucker;Cyrus M. Khan, MD
      May 31st 2023
      Podcast

      In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.

      Listen

      Jacobs and Peers Consider Third-Line Treatment in Relapsed/Refractory CLL

      Jacobs and Peers Consider Third-Line Treatment in Relapsed/Refractory CLL

      Targeted Oncology Staff
      March 14th 2025
      Article

      During a Case-Based Roundtable® event, Ryan W. Jacobs, MD, discussed a patient who received 2 prior lines of therapy for chronic lymphocytic leukemia.

      Read More

      CRISTALLO Study of Venetoclax/Obinutuzumab Achieves Superior MRD in CLL

      CRISTALLO Study of Venetoclax/Obinutuzumab Achieves Superior MRD in CLL

      Jordyn Sava
      February 20th 2025
      Article

      The CRISTALLO trial showed that venetoclax plus obinutuzumab achieved high minimal residual disease negativity as a frontline chronic lymphocytic leukemia therapy.

      Read More